摘要
目的探讨阿替普酶静脉溶栓治疗急性缺血性脑卒中患者的临床疗效及安全性。方法选取荥阳市人民医院2015年4月—2016年6月收治的急性缺血性脑卒中患者102例,根据不同的治疗分为对照组和观察组,各51例。对照组患者给予常规治疗,观察组患者在对照组基础上给予阿替普酶静脉溶栓治疗,两组患者均持续治疗7d。比较两组患者的临床疗效,治疗前及治疗后24 h、7 d美国国立卫生院卒中量表(NIHSS)评分、格拉斯昏迷量表(GCS)评分,统计并比较两组患者治疗期间不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者NIHSS评分、GCS评分比较,差异无统计学意义(P>0.05);治疗后24 h、7 d,观察组患者NIHSS评分均低于对照组,GCS评分高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿替普酶静脉溶栓急性缺血性脑卒中患者的临床疗效确切,可有效改善患者神经功能缺损程度及意识状态,且安全性高。
Objective To investigate the clinical efficacy and safety of alteplase intravenous thrombolysis in the treatment of patients with acute ischemic stroke. Methods A total of 102 cases of patients with acute ischemic stroke were selected from April 2015 to June 2016 in Xingyang People 's Hospital,which were divided into control group and observation group,51 cases in each group. The control group was treated with conventional therapy,observation group were treated with alteplase intravenous thrombolysis on the basis of control group,both groups were treated for 7 d. Clinical efficacy,NIHSS score,GCS score before treatment and after treatment of 24 h,7 d were compared between the two groups,and the incidence of adverse reactions were analyzed as well between the two groups. Results The clinical effect of observation group was better than control group( P〈0. 05). Before treatment,no significant differences of NIHSS score or GCS score was found between the two groups( P〈0. 05); after treatment of 24 h,7 d,observation group of NIHSS score was lower than control group,GCS score was higher than control group( P〈0. 05). There was no significant difference of the incidence of adverse reactions between the two groups( P〈0. 05). Conclusion Alteplase intravenous thrombolysis have a significant effect in the treatment of patients with acute ischemic stroke,it can effectively improve the patients' neurological deficit degree and consciousness and so far,and with high safety.
出处
《临床合理用药杂志》
2017年第3期7-8,11,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
卒中
溶栓
组织型纤溶酶原激活物
治疗结果
安全性
Stroke
Thrombolysis
Tissue-type plasminogen activator
Treatment outcome
Safety